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Metabolic syndrome (MS) is recognized as a risk factor for colon cancer (CC). However,
whether the cluster of metabolic changes that de!ne MS also in"uence CC prognosis
remains unclear. Thus, our aim was to investigate whether the presence of MS or any of
the MS individual components could provide prognostic information on tumor phenotype
and survival outcomes. Clinical and pathological data from patients with CC (n = 300) who
underwent surgical resection at a single tertiary hospital were retrospectively collected to
evaluate presence of MS components and diagnostic criteria, CC phenotype and disease
outcomes. Patients were allocated into two groups according to the presence or absence
of MS (n = 85 MS vs n = 83 non-MS). The overall prevalence of MS individual components
was 82.7% for increased waist-circumference (WC), 61.3% for high blood pressure (BP),
48.8% for low HDL-cholesterol, 39.9% for high fasting glucose, and 33.9% for
hypertriglyceridemia. Patients in the MS group presented smaller tumors (p = 0.006)
with lower T-stage (p = 0.002). High BP (p = 0.029) and hypertriglyceridemia (p = 0.044)
were associated with a smaller tumor size, while low-HDL (p = 0.008) was associated with
lower T-stage. After propensity score matching using age, tumor size and staging as
covariates high-BP (p = 0.020) and WC (p = 0.003) were found to in"uence disease-free
survival, but not overall survival. In conclusion, despite MS being an established risk factor
for CC, our data does not support the hypothesis that MS components have a negative
impact on disease extension or prognosis. Nevertheless, a protective role of BP and lipid
lowering drugs cannot be excluded.
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Araújo A and Faria G (2021) Effect of
Metabolic Syndrome and Individual





published: 04 March 2021
doi: 10.3389/fonc.2021.631257
INTRODUCTION
Colorectal cancer (CRC) is the third most common malignancy
worldwide with approximately 2 million new cases diagnosed in
2018 (1). Therefore, identifying clinically relevant prognostic
factors that could be used as a guidance for tailoring therapeutic
decisions should be considered a priority.
Abdominal obesity was previously identi!ed as one of the main
risk factors for colon cancer (CC) (2). Indeed, excess visceral
adiposity is often associated with a chronic low grade
in"ammatory state characterized by increased production of
in"ammatory cytokines and adipocytokines, which are responsible
for inducing several metabolic dysfunctions with carcinogenic
potential (2). Thus, the interest in characterizing the extent of the
impact of metabolic changes on cancer development and
progression has gradually increased; and most particularly focusing
on metabolic syndrome (MS) as a risk factor for CC (3, 4).
MS is a cluster of risk factors that includes abdominal obesity,
high blood-pressure (BP), dysglycemia or type 2 diabetes
mellitus, hypertriglyceridemia, and low high-density lipoprotein
cholesterol (HDL-c) (5), all of which have also been independently
associated with an increased risk of cancer (2, 4, 6). Despite
substantial interest in the relationship between MS and CC,
whether this cluster of metabolic abnormalities also in"uences
tumor characteristics and mortality remains unclear. Thus, we
aimed to further investigate whether MS or any of the MS
individual components could provide prognostic information
for tumor characteristics and survival outcomes. Since MS risk
factors can be easily assessed in routine clinical practice, if a
prognostic value could be identi!ed, this would be clinically
valuable to guide oncologists on therapeutic and lifestyle
interventions that might modify disease progression.
MATERIALS AND METHODS
Patients and Study Protocol
Data on all patients diagnosed with colon adenocarcinoma that
underwent surgical resection at a single tertiary public institution
between January 2010 and December 2015 were retrospectively
reviewed. Detailed clinical information retrieved from electronic
medical records, included clinical presentation, co-morbidities,
laboratory !ndings required for MS diagnosis, such as lipid
pro!le and fasting blood glucose, and pathological !ndings
required for CC tumor staging.
Metabolic Syndrome Criteria
Patients were classi!ed as havingMS whenever at least 3 out of the 5
individual components of the Harmonized Criteria were present,
namely: (i) abdominal obesity (waist circumference (WC) !94 cm
(male) or !80 cm (female) (Europid)); (ii) elevated triglycerides
(>150mg/dL) or ongoing treatment with triglyceride lowering drugs;
(iii) low HDL-c (<40 mg/dL (males) and <50 mg/dL (females) or
ongoing treatment with HDL-c raising drugs; (iv) high BP (systolic
!130 and/or diastolic !85 mm Hg) or ongoing treatment with
antihypertensive drugs; (v) fasting blood glucose !100 mg/dL or
ongoing treatment with glucose lowering drugs (5).
Colon Cancer Tumor Staging
Data on tumor pathological characteristics including primary
tumor location, larger tumor diameter, pathological stage, and
presence of lymph, vascular and peri-neural invasion were
retrieved from the electronic clinical records system. Primary
tumor location was considered as right-sided for tumors
involving from the cecum to the transverse colon and as left-
sided for tumors involving from the splenic "exure to sigmoid.
Colon cancer staging was performed according to the American
Joint Committee on Cancer (AJCC) criteria and the Duke’s
staging system.
Lymph node ratio (LNR) was calculated as the ratio between
the number of metastatic and dissected lymph nodes (LN).
Patients with node-negative disease were classi!ed as LNR=0%.
Patients with node-positive disease were classi!ed into LNR
categories de!ned according to the 50th percentile of patients
with node-positive disease, as previously described (7).
Patient follow-up data was retrieved until death or last visit.
Overall survival (OS) was de!ned as the time interval from the date
of diagnosis to the date of death. Recurrence-free survival (RFS) was
de!ned as the interval from the date of diagnosis to the date of tumor
recurrence or date of last follow-up. Disease-free survival (DFS) was
de!ned as the time interval from the date of diagnosis to date of
tumor recurrence, death or date of last follow-up.
This study protocol including clinical data accession was
granted approval by the Institutional Ethics Review Board
(2015.178(153-DEFI/142-CES).
Statistical Analysis
Continuous variables were expressed as mean ( ± standard deviation,
SD) or median (interquartile range (IQR)), according to data
distribution. Normality of the variables was determined by the
Shapiro-Wilk test. Categorical variables were expressed as counts
and proportions and compared with Chi-square test. Student’s t-test
andMann-Whitney U-test were used to evaluate differences between
groups in continuous variables, according to data distribution.
Propensity score matching between patients in the MS and no-
MS group was conducted to obtain matched data to reduce the
in"uence of data deviation and confounding variables in survival
analysis. Propensity scores were estimated accounting for the
following patient parameters: age, tumor size and TNM staging.
Matching was conducted by a 1:1 Mahalanobis distance optimal
matching within caliper set to 0.25 standard deviations of the logit of
the propensity score, as suggested by Rosenbaum and Rubin (8). The
quality of matching was evaluated by computing the standardized
difference in means for the two groups before and after matching.
Statistical analysis for recurrence and survival rates was determined
by the Kaplan–Meier method. The log-rank test was used for the
comparison of survival between patients’ groups. Cox proportional
hazard models were used to explore associations of MS and
individual components with survival outcomes. Multivariate
analysis using the Cox model was performed for all variables
found to be signi!cant in the univariate analysis. Statistical
signi!cance was considered for p<0.05. Data was stored and
analyzed using SPSS Statistics 25.0 (SPSS Inc., Chicago, IL, USA)
and XLSTAT 2020.5.1 (Addinsoft Inc., New York, USA).
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RESULTS
Detailed clinical data was retrieved from patients (n=300) that
underwent colon cancer surgical resection at a single public
hospital institution. Participants were excluded whenever the
histological diagnosis was other than colon adenocarcinoma
(n=36), the histological diagnosis was carcinoma in situ (n=5), the
information was incomplete to allow tumor staging (n=30),
information on any of the MS components was unavailable
(n=37), patients have had any anti-neoplastic treatment prior to
!rst evaluation at the hospital institution (n=17) or were lost to
follow-up (n=7). After exclusions, one hundred and sixty-eight
patients (n=168) were included in the analysis. The subjects were
divided into two groups based on the presence or absence of MS (n=
85 withMS vs n= 83 without MS). The baseline characteristics of the
patients are shown in Table 1. Patients withMS were predominantly
male (51.8%) and signi!cantly older (74 vs. 67 years old; p<0.001).
MS patients also had a signi!cantly larger waist circumference when
compared with patients without MS (105.6 vs. 101.2 cm; p<0.001).
The overall prevalence of MS components was 82.7% for elevated
WC, 61.3% for high BP, 48.8% for low HDL-c, 39.9% for
dysglycemia, and 33.9% for hypertriglyceridemia. No signi!cant
differences in red blood cell (RBC) counts, hematocrit or
hemoglobin between study groups were observed (Table 1).
No associations were found between MS and most of the clinical
or pathological variables assessed in this study, including primary
tumor location (p=0.258), lymph (p = 0.641), vessel (p = 0.062), or
neural (p=0.198) invasion nor distant metastatic disease (p = 0.787)
TABLE 1 | Patient’s characteristics according to metabolic syndrome status.
All patients (n=168) No MS (n=83) MS (n=85) p value
Age (years), mean (SD) 70 (12) 67 (14) 74 (9) <0.001
Male sex, n (%) 98 (58.3) 54 (65.1) 44 (51.8) 0.081
WC (cm), median (IQR) 102.4 (95.0–110.4) 101.2 (90.0–106.7) 105.6 (99.3–115.4) <0.001
MS risk factors, median (IQR) 3 (2–4) 2 (1–2) 4 (3–5) <0.001
Dysglycemia, n (%) 67 (39.9) 11 (13.3) 56 (65.9) <0.001
Low HDL-c, n (%) 82 (48.8) 10 (12.0) 72 (84.7) <0.001
High BP, n (%) 103 (61.3) 29 (34.9) 74 (87.1) <0.001
Hypertriglyceridemia, n (%) 57 (33.9) 4 (4.8) 53 (62.4) <0.001
Elevated WC, n (%) 139 (82.7) 60 (72.3) 79 (92.9) <0.001
RBC (x10^12/L), median (IQR) 4.5 (3.9–4.8) 4.6 (4.1–4.9) 4.4 (3.9–4.7) 0.059
Hematocrit (%), mean (SD) 37.2 (0.5) 37.6 (0.7) 36.8 (0.6) 0.424
Hemoglobin (g/dL), mean (SD) 12.1 (0.2) 12.2 (0.3) 11.9 (0.2) 0.355
Tumor location, n (%)
Left side 100 (59.5) 53 (63.9) 47 (55.3) 0.258
Right side 68 (40.5) 30 (36.1) 38 (44.7)
Tumor size (cm), median (IQR) 4.0 (3.0–5.5) 4.5 (3.5–5.5) 4.0 (3.0–5.0) 0.006
T stage, n (%)
1/2 42 (25.0) 12 (14.5) 30 (35.3) 0.002
3/4 126 (75.0) 71 (85.5) 55 (64.7)
N stage, n (%)
0 102 (60.7) 48 (57.8) 54 (63.5) 0.185
1 42 (25.0) 19 (22.9) 23 (27.1)
2 24 (14.3) 16 (19.3) 8 (9.4)
Metastatic LN, median (IQR) 0 (0–2) 0 (0–3) 0 (0–1) 0.277
Retrieved LN, median (IQR) 14 (10–21) 16 (11–23) 14 (10–18) 0.052
LNR, median (IQR) 0.15 (0.08–0.36) 0.22 (0.09–0.36) 0.12 (0.07–0.36) 0.159
LNR, n (%)
LNR = 0% 103 (61.3) 49 (59.0) 54 (63.5) 0.332
LNR <15% 32 (19.0) 14 (16.9) 18 (21.2)
LNR !15% 33 (19.6) 20 (24.1) 13 (15.3)
M stage, n (%)
0 135 (80.4) 66 (79.5) 69 (81.2) 0.787
1 33 (19.6) 17 (20.5) 16 (18.8)
AJCC Classi!cation 0.285
Dukes Classi!cation, n (%)
A 36 (21.4) 11 (13.3) 25 (29.4) 0.070
B 48 (28.6) 28 (33.7) 20 (23.5)
C 52 (31.0) 28 (33.7) 24 (28.2)
D 32 (19.0) 16 (19.3) 16 (18.8)
Lymphatic Invasion, n (%) 86 (51.2) 44 (53.0) 42 (49.4) 0.641
Vascular Invasion, n (%) 65 (38.7) 38 (45.8) 27 (31.8) 0.062
Perineural Invasion, n (%) 49 (29.2) 28 (33.7) 21 (24.7) 0.198
Relapse, n (%) 46 (27.4) 24 (52.2) 22 (47.8) 0.659
Death, n (%) 45 (26.8) 21 (46.7) 24 (53.3) 0.668
Continuous variables are presented as mean ( ± SD) or median (IQR). Categorical data are presented as n (%). BP, Blood Pressure; IQR, Interquartile range; LN, lymph node; LNR, lymph
node ratio; MS, metabolic syndrome; RBC, Red Blood Cells; SD, Standard deviation; WC, waist circumference.
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(Table 1). No residual tumor was found after primary tumor
resection in all patients (R0). Patients in the MS group had less
advanced T-stage (p = 0.002) and a signi!cantly smaller median
tumor size than the patients in the no-MS group (4.0 cm vs. 4.5 cm;
p = 0.006) (Table 1). No differences were found between groups
regarding the disease stage by the AJCC (p = 0.285)
(Supplementary Table 1) nor Dukes (p = 0.070) classi!cation
(Table 1). The median LN harvested during surgery was 14 (range,
3–74), with no signi!cant differences between the groups despite the
marginally lower LN number in the MS group (14 vs. 16; p = 0.052).
Median LNR of node-positive patients was 0.15, setting LNR
threshold at 15%. LNR categories were stablished according to the
extension of LN involvement in LNR<15% and LNR!15%. No
association was found between MS and LNR (p = 0.332) or
metastatic LN (p = 0.277) (Table 1).
The effect of each MS component in tumor characteristics
revealed that high BP (p=0.029) and hypertriglyceridemia
(p=0.044) were associated with a smaller tumor size (Table 2),
while low-HDL (p=0.008) was associated with lower T-stage
(Table 3).
In the propensity score!matching analysis, 60 patients in the MS
group and 60 patients in the no!MS group were matched and
analyzed. There was no statistical signi!cance in the adjusted
covariates of the 120 patients after PS matching (Supplementary
Table 2). Balance between groups could also be observed in the
histograms of the propensity scores before and after the matching
(Supplementary Figure 1). The Kaplan-Meier analysis showed no
statistical signi!cance in OS curves for MS or its individual
components (Figure 1). High BP was associated with worse DFS
(p=0.020) (Figure 2D) but no differences were observed in RFS
(p=0.071) (Figure 3D). In contrast, elevated WC was associated
with improved DFS (p=0.003) (Figure 2F) and RFS (p=0.020)
(Figure 3F). No other statistically signi!cant differences were found
in the Kaplan-Meier survival curves (Figures 2A–C, E and Figures
3A–C, E). Data on the effects of MS and its components as
prognostic factors for OS, RFS and DFS are provided in Table 4.
Univariate Cox regression analysis revealed that high BP [hazard
ratio (HR), 2.11; 95% con!dence interval (CI), 1.11 –4.04] and WC
[hazard ratio (HR), 0.40; 95% con!dence interval (CI), 0.21 –0.75]
were independent prognostic factors for DFS (Table 4). After
multivariate analysis both variables retained signi!cance (Table 4).
DISCUSSION
Epidemiological data showed that MS and individual MS
components confer a higher risk for adenoma and CC (4, 9–
11). In fact, several in"ammatory cytokines and adipokines
associated with abdominal obesity and insulin resistance were
hypothesized to be the pathophysiological link between MS and
CC (3, 12). In this study, we aimed to evaluate whether the
presence of MS or individual MS components could predict CC
tumor characteristics and disease prognosis.
Our results show an association between MS and early T-stage
(35.3 vs 14.5%, p=0.002). When assessing the impact of each
individual component, only low HDL-c maintained this
association (p=0.008). Of notice, all patients in this group were
under lipid-lowering drugs (statins, !brates or other). As elevated
total cholesterol and LDL-c levels were demonstrated to have
deleterious effects in non-metastatic CRC survival (13), a possible
protective role for statins and other cholesterol-lowering agents,
such as ezetimibe, has been suggested (14, 15). In fact, the long-term
use of statins has been associated with less advanced tumor stage,
lower frequency of distant metastasis and better overall survival
(16). The mechanism of action of cholesterol-lowering agents in CC
is still unclear. Despite the fact that statins and ezetimibe were
shown to interfere with several cancer-related processes such as
in"ammation, cell proliferation, angiogenesis, apoptosis, and
metastization, recent studies failed to demonstrate that statins
improve CC survival, regardless of KRAS mutation status (17, 18).
Our primary !ndings also revealed a smaller tumor size in the
MS group (4.0 vs 4.5 cm, p=0.006), particularly in the group of
patients with high BP (p=0.029). A possible explanation for these
results could be related to the recently demonstrated anti-
TABLE 2 | Association of individual components of MS with tumor size.
MS Component Tumor size (cm) p value
Dysglycemia, median (IQR) 0.946
Yes 4.2 (3.0–5.5)
No 4.0 (3.1–5.3)
Low HDL-c, median (IQR) 0.229
Yes 4.0 (3.0–5.5)
No 4.5 (3.5–5.5)
High BP, median (IQR) 0.029
Yes 4.0 (3.0–5.0)
No 4.5 (3.5–5.5)
Hypertriglyceridemia, median (IQR) 0.044
Yes 4.0 (3.0–5.0)
No 4.5 (3.5–5.5)
Elevated WC, median (IQR) 0.365
Yes 4.0 (3.0–5.5)
No 4.1 (3.5–5.8)
BP, Blood pressure; IQR, Interquartile range; MS, Metabolic Syndrome; WC, Waist
circumference.
In bold: p-values with statistical signi!cance.
TABLE 3 | Association of individual components of MS with T-stage.
MS Component T-stage p value
1/2 3/4
Dysglycemia, n (%) 0.056
Yes 20 (47.6) 81 (64.3)
No 22 (52.4) 45 (35.7)
Low HDL-c, n (%) 0.008
Yes 14 (33.3) 72 (57.1)
No 28 (66.7) 54 (42.9)
High BP, n (%) 0.410
Yes 14 (33.3) 51 (40.5)
No 28 (66.7) 75 (59.5)
Hypertriglyceridemia, n (%) 0.074
Yes 23 (54.8) 88 (69.8)
No 19 (45.2) 38 (30.2)
Elevated WC, n (%) 0.125
Yes 4 (9.5) 25 (19.8)
No 38 (90.5) 101 (80.2)
BP, Blood pressure; MS, Metabolic Syndrome; WC, Waist circumference.
In bold: p-values with statistical signi!cance.
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FIGURE 1 | Kaplan-Meier overall survival (OS) curves: (A) patients with and without metabolic syndrome (MS); (B) patients with and without dysglycemia (fasting
plasma glucose !100 mg/dl); (C) patients with and without low HDL-c; (D) patients with and without high blood pressure (BP); (E) Patients with and without
hypertriglyceridemia; (F) patients with and without elevated waist-circumference (WC).
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FIGURE 2 | Kaplan-Meier disease-free survival curves (DFS): (A) patients with and without metabolic syndrome (MS); (B) patients with and without dysglycemia
(fasting plasma glucose !100 mg/dl); (C) patients with and without low HDL-c; (D) patients with and without high blood pressure (BP); (E) patients with and without
hypertriglyceridemia; (F) patients with and without elevated waist-circumference (WC).
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FIGURE 3 | Kaplan-Meier recurrence-free survival curves (RFS): (A) patients with and without metabolic syndrome (MS); (B) patients with and without dysglycemia
(fasting plasma glucose !100 mg/dl); (C) patients with and without low HDL-c; (D) patients with and without high blood pressure (BP); (E) patients with and without
hypertriglyceridemia; (F) patients with and without elevated waist-circumference (WC).
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proliferative and apoptotic potential of antihypertensive drugs,
such as angiotensin-converting-enzyme inhibitors (ACEi) and
angiotensin receptor blockers (ARB) (19–22). In fact, there are
several common links between hypertension and tumor
development, since angiogenesis and oxidative stress play an
important role in both conditions by modulating in"ammation,
vascular tone, cell growth and differentiation (23). Chen et al.
reported that the ACEi captopril and the ARB losartan/
irbesartan induced a dose-dependent inhibition of cell
proliferation and VEGF secretion in esophageal squamous
carcinoma cell lines (20). In addition, Alhusban et al.
demonstrated that clinically relevant doses of candesartan
inhibited growth of prostate tumor xenografts in mice by
decreasing VEGF expression via AT1 inhibition. Furthermore,
candersartan was demonstrated to reduce vascular lumen size
and increase vessel wall thickness, inhibiting tumor vascular
permeability and perfusion, impairing neovascularization and
thus nutrient supply (22).
In this study, a marginally lower number of LN was retrieved in
the MS group (14 vs 16; p=0.052), in accordance with previous
reports where patients without MS were more likely to have !12 LN
retrieved (24). This is likely related to the fact that visceral obesity is
an important contributor to increased surgical dif!culty by limiting
accessibility to LN located deep in the adipose tissue surrounding
the major vessels (25). Previous !ndings support that the extent of
lymphadenectomy may in"uence the pathologic N stage, as the
number of positive LN increases in proportion to the number of
dissected nodes (26). Therefore, in addition to nodal invasion,
several studies also evaluated the prognostic value of LNR as a
surrogate endpoint regardless of total nodes in CRC outcomes (26,
27). However, the existing studies regarding the effect of MS in CC
outcome focus primarily on the number of dissected LN (24, 28).
For that reason, to our knowledge the impact of MS on LNR has not
been addressed. Still, we found no association between MS and the
extent of nodal involvement according to metastatic LN (p=0.277)
or LNR (p=0.332).
No signi!cant relationship was identi!ed between MS and
other tumor pathological features, such as tumor primary
location, pathological staging and local or distant invasion.
These !ndings are in accordance with several previous studies
conducted in this !eld (13, 28, 29).
In this study, we found no association between MS or any
individual MS component and CC OS. An inconsistent
association between MS and its individual components on CC
mortality and disease recurrence has been reported in previous
epidemiologic studies. A large retrospective cohort of 36.079
patients with CC found no association of MS with OS or RFS.
However, the authors attributed this result to the impact of
individual components since diabetes and hypertension
decreased survival, whereas dyslipidemia revealed a protective
effect improving OS and RFS (24). In another study, MS, diabetes
and hypertension had no prognostic impact in OS in non-
metastatic CRC patients. On the contrary, patients without MS
had improved DFS (p=0.014) and cumulative 3-, and 5-year DFS
(p=0.039, p=0.044, respectively) (13). These !ndings seem to
suggest that, regardless of more favorable tumor characteristics,
co-morbidities associated with MS, such as dysglycemia, can
have a deleterious effect on survival. In our study, patients with
higher WC showed improved DFS and RFS. Since a large
percentage of patients with high-WC were under treatment
with lipid lowering drugs, this result suggests that DFS
improvement could be related to the protective effect of these
agents as discussed above. Nevertheless, despite lipid lowering
agents being suggested to have bene!cial effects by limiting
tumor in!ltration these may not have the necessary robustness
to in"uence CC prognosis, as OS was not affected. Previous
studies focusing on the potential role of obesity in CRC survival
has yielded heterogeneous results. Additionally, recent results
revealed that a normal weight could be protective for
cardiovascular death, but not CRC recurrence (30). Despite its
possible association with smaller tumor size at diagnosis, high BP
demonstrated to negatively affect DFS, revealing as an
independent prognostic factor after multivariate analysis [hazard
ratio (HR), 2.12; 95% con!dence interval (CI), 1.11 –4.05].
Hypertension is a known side effect of all angiogenesis
inhibitors used in the treatment of CC (31). Therefore, for
individuals with high BP at baseline, it may act as a barrier to
the initiation of such treatment, dose restrictions or premature
discontinuation, and thus affecting DFS.
The con"icting results on the effect of MS in CC outcomes
reported by clinical studies may be explained by the different
de!nitions of MS in different populations. Since insulin resistance
was thought to be one of the major pathophysiological mechanisms
of MS, this remained a precondition for the World Health
Organization (WHO) de!nition of MS (32). Likewise, since
central obesity is also considered one of the key elements for
TABLE 4 | Univariate survival analysis of MS and components for RFS, DFS and OS of the matched patients.
Variable OS DFS DFS RFS
Univariate Univariate Multivariate Univariate
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
MS 1.34 (0.67–2.67) 0.412 1.08 (0.62–1.87) 0.793 – – 1.13 (0.59–2.18) 0.715
Dysglycemia 1.64 (0.83–3.25) 0.153 1.05 (0.61–1.84) 0.853 – – 0.87 (0.45–1.71) 0.690
Low HDL-c 1.28 (0.64–2.52) 0.500 1.07 (0.62–1.86) 0.813 – – 0.97 (0.50–1.86) 0.915
High BP 1.36 (0.63–2.94) 0.433 2.11 (1.11–4.04) 0.023 2.12 (1.11–4.05) 0.023 1.98 (0.93–4.20) 0.076
Hypertriglyceridemia 1.06 (0.52–2.16) 0.869 0.85 (0.45–1.53) 0.594 – – 0.83 (0.42–1.66) 0.597
WC 0.62 (0.29–1.35) 0.228 0.40 (0.21–0.75) 0.005 0.39 (0.21–0.75) 0.004 0.41 (0.19–0.89) 0.024
BP, Blood pressure; DFS, Disease-free survival; HR, Hazard ratio MS, Metabolic Syndrome; OS, Overall survival; RFS, Relapse-free survival; WC, waist circumference.
In bold: p-values with statistical signi!cance.
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metabolic disorders the International Diabetes Federation (IDF)
considers abdominal obesity a prerequisite for MS diagnosis (33).
Thus, the use of WHO and IDF criteria may lead us to conclude
that a non-diabetic or non-overweight patient is healthy, although it
is possible that the individual is metabolically unhealthy. The
National Cholesterol Education Program (NCEP) Adult
Treatment Panel III (ATP III) and the Harmonized Criteria of
the Joint Interim Societies require that patients meet at least 3 of the
5 MS criteria and unlike WHO or IDF de!nitions, do not require
any speci!c criteria (5, 34). The Harmonized Criteria and IDF use
population-speci!c cut-off points for WC measurement (5, 33).
Additionally, several studies performed in the Asian population use
the criteria de!ned by the Chinese Diabetes Society (35). These
criteria differ from those described above in several aspects,
including the use of body mass index as a measure of obesity, the
merging of lipid deviations into one criterion and the use of
different cutoff values for blood pressure, glucose and HDL-c
(35). Con"icting results may also arise from the fact that most
studies fail to control for cancer type (i.e., colon vs rectum) and
treatment, which can particularly affect survival analysis.
Our results must also be interpreted in the light of study
limitations. First, this was a retrospective single-center study,
which constrains sample size and may cause some selection bias.
Therefore, some predictive associationsmay have beenmissed due to
sample size that hampers the robustness of our conclusions and
limits generalization of the conclusions. Second, the impact of
different treatment plans for MS individual components on patient
outcome could not be determined. This can be an important source
of bias, since most patients under treatment for dyslipidemia were
treated with statins, which target mostly LDL-c and HDL-c in a
smaller extension. Third, due to the retrospective nature of the study,
additional potential confounding factors such as family history of
cancer, cigarette smoking, alcohol consumption, dietary habits and
physical activity were not evaluated. Data on these factors would be
of great interest since these are known to play a dual role in the
pathogenesis of metabolic syndrome and cancer, which may affect
survival. In addition, since patients are referred to our institution
from primary care centers for elective treatment, data on whether
CRC diagnosis was due to screening or symptoms driven, could not
be collected. This relevant information if available could expand the
possibility of hypothesis testing. A further limitation of our study
may be the lack of gender strati!cation since some data suggest a
higher risk and worse outcome in men (4, 10, 28).
Despite these limitations, our study provides a better
understanding of the link between MS and CC phenotype and
outcome. Although several studies point to a higher risk of CC in
metabolically dysfunctional patients, this deleterious effect on tumor
aggressiveness could have been counterbalanced by the protective
effect of statins and ACEi/ARB. This study provides relevant
information for routine clinical practice, since this applies to a
considerable proportion of patients with CC that also present MS
and are under blood pressure, lipid and glucose lowering drugs.
Further investigations should be designed using prospective clinical
data with extensive data onmedication, weight variation and clinical
parameters such as blood pressure, glucose and lipid serum levels, to
extend our !ndings and also address gender-related in"uences.
In conclusion, despite the recognized relationship between several
MS components and cancer risk, our data shows that patients with
this metabolic dysfunction seem to have more favorable tumor
characteristics, such as primary tumor diameter and disease
extension. Therefore, our !ndings do not support the hypothesis
that MS has a negative impact on CC prognosis. However, given the
fact that most patients with MS were under treatment with BP and
lipid lowering drugs, the potential in"uence of the protective role of
these pharmacological agents cannot be excluded.
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